Shopping Cart
Remove All
  • TargetMol
    Your shopping cart is currently empty

Sudubrilimab (Synonyms: HS636)

Catalog No. T77189 Copy Product Info
🥰Excellent
Sudubrilimab is an innovative bifunctional fusion protein designed to simultaneously target two key inhibitory pathways in the tumor microenvironment: the PD-1/PD-L1 immune checkpoint and the TGF-beta signaling axis. The compound consists of a humanized anti-PD-L1 monoclonal antibody fused to the extracellular domain of TGF-beta receptor II (TGFBR2-ECD). Serving as an essential tool for investigating the reversal of tumor immunosuppression and the enhancement of effector cell function, its design aims to overcome resistance to single-target therapies through synergistic action.

Sudubrilimab

Copy Product Info
🥰Excellent
Catalog No. T77189
Synonyms HS636

Sudubrilimab is an innovative bifunctional fusion protein designed to simultaneously target two key inhibitory pathways in the tumor microenvironment: the PD-1/PD-L1 immune checkpoint and the TGF-beta signaling axis. The compound consists of a humanized anti-PD-L1 monoclonal antibody fused to the extracellular domain of TGF-beta receptor II (TGFBR2-ECD). Serving as an essential tool for investigating the reversal of tumor immunosuppression and the enhancement of effector cell function, its design aims to overcome resistance to single-target therapies through synergistic action.

Sudubrilimab
Cas No. 2387417-06-1
Pack SizePriceUSA StockGlobal StockQuantity
1 mg$290-In Stock
5 mg$871-In Stock
10 mg$1,390-In Stock
For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)
Add to Cart
Add to Quotation
For research use only—not for human use. No sales to individuals. Use as intended only.
Questions
TargetMol
View More

Batch Information

Select Batch
Purity:96.1% (SDS-PAGE); 98.4% (SEC-HPLC)
Appearance:Liquid
Color:Transparent
Contact us for more batch information

Product Introduction

Bioactivity
Description
Sudubrilimab is an innovative bifunctional fusion protein designed to simultaneously target two key inhibitory pathways in the tumor microenvironment: the PD-1/PD-L1 immune checkpoint and the TGF-beta signaling axis. The compound consists of a humanized anti-PD-L1 monoclonal antibody fused to the extracellular domain of TGF-beta receptor II (TGFBR2-ECD). Serving as an essential tool for investigating the reversal of tumor immunosuppression and the enhancement of effector cell function, its design aims to overcome resistance to single-target therapies through synergistic action.
In vitro
In PD-L1 and TGF-beta binding assays, Sudubrilimab bound specifically to both targets and enhanced IFN-gamma production in T-cell activation assays [1].
SynonymsHS636
Reactivity
Human
Application
Functional assay
Antibody Type
Monoclonal
FormulationSupplied as a sterile solution in a buffered formulation system (e.g., phosphate-, citrate-, or amino acid-based). Please refer to the CoA for lot-specific composition.
Endotoxin<1.0 EU/mg
Related Conjugates and Formulations
Conjucates
Unconjugated
Antigen Details
Gene ID
Uniprot ID
TargetB7-H1/PD-L1/CD274
Chemical Properties
Cas No.2387417-06-1
Antibody Information
IsotypeHuman IgG1 kappa
Recommended Isotype Control
Storage & Solubility Information
StorageStore at -20°C Shipping with blue ice/Shipping at ambient temperature.

Citations

Calculator

  • Dilution Calculator
  • Reconstitution Calculator
Related Tags: buy Sudubrilimab | purchase Sudubrilimab | Sudubrilimab cost | order Sudubrilimab | Sudubrilimab chemical structure | Sudubrilimab in vitro